Clinical Trial Update: Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety, tolerability, and immunogenicity of the UB 311 vaccine in Alzheimer's disease patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• UB 311

Snippet

Sponsor: United Biomedical | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED